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Background: Lung cancer remains the leading cause of cancer death worldwide with 15-20% occurring in 
never-smokers. To assess genetic determinants for prognosis among never smokers, we conducted a 
genome-wide investigation in the International Lung Cancer Consortium(ILCCO).  
Methods: Genomic and clinical data from 1569 never-smoking lung cancer patients of European 
ancestry from 10 ILCCO studies were included. Hazard ratios(HRs) and 95% confidence intervals of 
overall survival were estimated. We assessed whether the associations were mediated through mRNA 
expression based 1553 normal lung tissues from the Lung expression quantitative trait loci(eQTL) 
dataset and GTEx. For cross-ethnicity generalization, we assessed the associations in a Japanese 
study(N=887). 
Results: One locus at 13q22.2 was associated with lung adenocarcinoma survival at genome-wide level, 
with carriers of rs12875562-T allele exhibiting poor prognosis(HR=1.71(1.41-2.07), p=3.60x10-8), and 
altered mRNA expression of LMO7DN in lung tissue(GTEx, p=9.40x10-7; Lung eQTL dataset, p=0.003). 
Furthermore, two of 11 independent loci that reached the suggestive significance level(p<10-6) were 
significant eQTL affecting mRNA expression of nearby gene in lung tissues, including CAPZB at 1p36.13 
and UBAC1 at 9q34.3. One locus encoding NWD2/KIAA1239 at 4p14 showed associations in both 
European(HR=0.50(0.38-0.66), p=6.92x10-7) and Japanese populations(HR=0.79(0.67-0.94), p=0.007). 
Conclusions: Based on the largest genomic investigation on the lung cancer prognosis of never smokers 
to date, we observed that lung cancer prognosis is affected by inherited genetic variants. 
Impact: We identified one locus near LMO7DN at genome-wide level and several potential prognostic 
genes with cis-effect on mRNA expression. Further functional genomics work is required to understand 





With over 1 million deaths each year, lung cancer continues to be the leading cause of cancer mortality 
worldwide, and the five-year survival rate remains low at only 10 to 20%(1,2). While it is well established 
that tobacco smoking is the primary cause of lung cancer, inherited genetic variations has also been 
established as etiological factors through genome-wide association studies (GWAS), which identified 
susceptibility loci  including CHRNA3/5, TERT-CLPTM1L, the HLA/MHC region, CHEK2 and more in the 
last decade(3-9). 
Approximately 15 to 20% of lung cancer cases occur in individuals who are lifelong never smokers 
(10,11).  Many studies have shown significant differences in the etiology and clinical characteristics 
between never and ever smokers, and lung cancer in never smokers is being recognized as a distinct 
disease entity. Most notably, smokers and never smokers have different histological presentation with  
adenocarcinoma being the main histological type among never smoking patients (10), and never 
smokers have a higher prevalence of EGFR mutations and those with EGFR mutations show longer 
survival after treatment with EGFR inhibitors than ever smokers do. Additional features that distinguish 
lung cancer in never smokers and ever smokers are differences in their somatic mutations and 
methylation profiles (12,13).   
Inherited genetic variation has been hypothesized to influence lung cancer survival and several genome-
wide association studies (GWAS) were performed with a focus on overall survival (14); in early stage 
lung cancer patients (15,16), patients who received platinum based chemotherapies (17-19), and 
advanced non-small cell lung cancer (20,21), although most studies have relatively modest sample sizes 
ranging from 100 to 400 lung cancer patients. Moreover, we hypothesize that there are distinctive 
genetic factors contribute to lung cancer prognosis in smokers and never smokers, and analyzing never 
smokers separately would provide a greater insight on the genetic components of lung cancer survival 
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for this specific population. To increase our power for genomic discovery, we conducted a meta-analysis 
of ten GWAS with clinical prognosis data based on a total of 1569 never-smoking lung cancer patients of 
European ancestry in a two-stage analysis. The generalizability of the candidate association across 
ethnicity was tested in the Japanese non-smoking population in the second stage. The potential 
functional significance of the genetic regions related to prognosis was investigated using expression 
quantitative trait loci (eQTL) analysis based on four independent studies from the Universities of Laval, 
University of British Columbia and Groningen, and the Genotype-Tissue Expression (GTEx) data (22,23).  
MATERIALS and METHODS 
Description of participating studies  
A total of 12 studies in the International Lung Cancer Consortium (ILCCO) participated in this analysis, 
including 10 lung cancer GWAS of European populations and 2 studies in Japanese populations to asses 
for generalizability. Never smokers were defined as individuals who smoked fewer than 100 cigarettes 
during their lifetime, with the exception of Liverpool Lung Project in which the definition was individuals 
who smoked 10 cigarettes per week regularly (among those 98.5% also fit under the former definition). 
All participants provided written informed consent and research protocols of all studies were reviewed 
and approved by the local institutional review boards of each participating study.  Information of each 
study is summarized in Table 1, and included in the Supplementary Materials.  
Genotyping and Imputation  
Genotyping in each study was conducted using Illumina HumanHap300K, 370K, 610K, 660K, 
OmniExpress or OncoArray. In general, the quality control procedures were similar across studies with 
exclusion of variants based on low call rate (<90%), and low minor allele frequency (<1%). Individuals 
with high missing rate (>5 or 10%), gender discrepancies, unexpected duplicates or relatedness were 
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excluded. Details of genotyping and quality control procedures as applied to the lung cancer OncoArray 
project have been previously published (24). After applying quality control steps and restricting to 
genotyped individuals of European ancestry with no smoking history and complete clinical follow-up 
information, data were available on a total of 1,569 never smoking lung cancer patients, including 208 
from Toronto, 327 from MDACC, 349 from Mayo, 59 from Central Europe, 92 from Harvard study and 
534 in the five studies genotyped in the OncoArray project. The key characteristics of all participating 
studies are summarized in Table 1. 
To facilitate the meta-analysis across genotyping platforms, genotype imputation was conducted in each 
study based on the March 2012 release of the 1000-Genomes Project. The Toronto and Mayo Clinic 
studies were imputed using IMPUTE2 (25-27), and the IARC-Central Europe and Harvard studies were 
imputed using MaCH software (28). Variants that were not present in any genotyping array, or with sub-
optimal imputation quality were excluded from the analysis based on IMPUTE2 Info < 0.3 and MACH 
RSQR < 0.3. After applying quality control filters, 629,283 SNPs were available for the meta-analysis. For 
the Japanese GWAS study, the 887 lung cancer patients from National Cancer Center Hospital and Aichi 
Cancer Centre were genotyped using Illumina HumanOmini1-Quad and Illumina 660W. The Japanese 
study was imputed using IMPUTE2. Standard quality control steps applied to remove potential errors 
and biases have been previously described (29). Briefly, individuals with gender discrepancies, low call 
rates (<98%) and first-degree relatives were excluded, and variants with Hardy-Weinberg Equilibrium (P 





Study-specific analysis of GWAS data  
Overall survival time was defined as the time from date of lung cancer diagnosis to date of death or the 
last known date alive. Cox proportional-hazards model was applied to assess marginal effects of patient 
characteristics on lung cancer survival. Genomic inflation factor was estimated by comparing observed 
and expected p-values. Quantile-quantile (Q-Q) plots were used to assess the extent to which the 
observed distribution of the test statistic follows the expected distribution for each study. OncoArray 
project data were pooled and analysed as one study as they were all genotyped and processed at the 
same time. The analytical process was summarized in Supplementary Figure 1. 
For each variant that passed QC procedures as described, multivariate Cox proportional hazards 
regression was used to assess the association of lung cancer survival within each study. The probabilistic 
genotype dosage model was used for the main analysis and included potential confounding factors that 
might influence patient survival including age (as a continuous variable), sex (male or female), clinical 
stage (IA-IIIA, IIIB-IV), and where available, treatment information. To limit inflation of the calculated 
test-statistics due to population sub-structure, each study was independently adjusted by the top two to 
six principal components (PCs) (30). The Japanese studies were adjusted by the top five PCs. Hazard 
Ratios (HR) and their corresponding 95% confidence intervals (95% CI) for survival were computed based 
on cox regression models.  
Survival rates were estimated using the Kaplan-Meier method and median survival times were 
calculated based on diagnosis and death dates. Log-rank tests were used to examine for differences 




Meta-Analysis of GWAS data  
A fixed-effects meta-analysis was performed to combine study-specific hazard ratios (HR) of sequence 
variants using an inverse variance-based weighting method implemented in the METAL program (31). 
The combined estimates were only computed for those variants observed in at least three studies. I2 
statistic was calculated to assess the proportion of the total variation due to heterogeneity, and I2 > 75% 
and PHET < 0.05 were applied to filter out variants with high study heterogeneity (32).  
Given the biological heterogeneity across lung cancer histological types, we have also conducted 
additional analysis restricted to 1,065 adenocarcinoma patients, as this is the predominant histological 
type of never smokers. We did not consider a subgroup analysis for other histology types due to small 
sample size.  For genetic variants with p-value of less than 10-6, we assessed the generalizability based 
on the Japanese study.  All statistical tests were two-sided.  
Functional Significance 
Genetic variants with combined p-value less than 10-6 for lung cancer survival were followed up for 
potential functional significance through an expression quantitative trait loci (eQTL) investigation based 
on the Lung eQTL dataset, which includes 3 independent studies and GTEx data. All data sources have 
been described previously (22,23). Briefly for the Lung eQTL dataset, whole-genome gene expression 
profiling in the lung was performed on a custom Affymetrix array (GPL10379). Microarray pre-processing 
and quality controls were conducted as previously described (22). Genotyping was carried on the 
Illumina Human 1M-Duo BeadChip array. Only cis-eQTL were considered in this study, testing probe sets 
located within 1 Mb up and downstream of the SNPs associated with lung cancer survival. Genotypes 
and gene expression were available in a total of 1038 individuals including 409 from Laval University, 
287 patients from the University of British Columbia (UBC), and 342 from University of Groningen(33). 
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Association tests were carried in each cohort and then meta-analyzed using Fisher’s method. Expression 
QTL analyses were performed adjusted for age, sex and smoking status. In addition, the Genotype-
Tissue Expression (GTEx) database (http://www.gtexportal.org/home/) of RNAseq analysis was queried 
to examine the functional association between candidate variants and expressions of nearby genes in 
515 human lung tissues (Release V7). 
 
RESULTS 
Study Population Characteristics 
The baseline characteristics of 1,569 never-smoking lung cancer patients with European ancestry and 
887 Asian lung cancer patients from Japan are shown in Table 1. All studies had similar age distribution 
with mean age at diagnosis of approximately 62 years across all studies with European ancestry. As 
expected, approximately two-thirds of the patients were females, and lung adenocarcinoma was the 
primary histological type in all studies. Median follow-up time (MFT) ranged from 26 months in the 
MDACC-OncoArray study to 126 months in the Mayo Clinic study. Overall, 53% of patients were 
diagnosed with localized stage (I-IIIA) and the remaining 47% with advanced stage (IIIB-IV). The 
association between key patient characteristics and survival is shown in Supplementary Table 1. As 
expected, clinical stage is the most prominent factor associated with survival.  Treatment information 
was available in five of the studies as surgery, chemotherapy or radiation.  
Genetic variants associated with lung cancer survival  
A total of 629,283 single nucleotide variants (SNVs) were included in the combined analysis after quality 
control filtering procedures previously described. The distribution of the bottom 95% of P-values was 
similar to the expected distribution, and the genomic control parameter was 1.02 based on the 
combined analysis. The associations between genetic variants and lung cancer overall survival for all 
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lung cancer and adenocarcinoma patient across chromosomes are shown in Manhattan plots 
(Supplementary Figure 2). The main findings for overall survival among all lung cancer patients and 
adenocarcinoma patients are summarized in Table 2.  For lung cancer overall, no regions reached 
genome-wide significance and four variants at 1p22.3, 8q2.3, 9q31.3 and 10p14 were associated with 
overall survival at p-value less than 10-6 (Supplementary Figure 3A-3D).   
When restricting the analysis to 1,065 lung adenocarcinoma patients, the intergenic region at 13q22.2 
(represented by rs12875562) reached significance GWAS level with T allele was associated with shorter 
survival time (HR = 1.71, 95%CI=1.41-2.07, P=3.60x10-8) (Table 2, Figure 1). In addition, seven other loci 
had suggestive evidence of association with overall survival at p-value ≤ 10-6(Table 2).  Among those loci 
that showed suggestive evidence, it was worthwhile to mention that loci encoding CAPZB gene at 
1p36.13 (represented by rs214346), and encoding UBAC1 gene at 9q34.3 (represented by rs6569) both 
conferred consistent association across studies with HR of 0.72 (95%CI=0.63-0.82, p=5.86x10-7) and 0.72 
(95%CI= 0.63-0.82, p=5.94x10-7), respectively (Figure 2a and Figure 3a).  The genetic locus that conferred 
the most distinctive survival patterns by genotype is located in 11q14 (represented by rs17148028) 
encoding DLG2 (Table 2 and Supplementary Figure 3i) with HR of 0.48 (0.36-0.64) with carriers of T allele 
exhibiting better prognosis. The forest plots and regional plots of the remaining loci are shown in the 
Supplementary Figure 3.  
Among the total 12 loci, the locus encoding NWD2/KIAA1236 located at 4p14 (represented by 
rs17603438) also showed an association with lung cancer survival in the Japanese cohort. The major 
allele A was correlated with longer survival time in both the European cohorts (HR = 0.50, 95%CI= 0.38-
0.66, P=6.92x10-7) and in the Japanese study (HR = 0.79, 95%CI= 0.67-0.94, P=0.0072). No other loci 
showed generalizable association across ethnic groups. 
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Supplementary Table 2 summarizes the result of genetic variants previously reported to be associated 
with lung prognosis based on two of the studies included in this analysis (34).  Three of the eight loci 
remained to be nominally significant (Supplementary Table 2) at p-value of 10-2 to 10-4 based on ten 
studies. No follow-up analyses were performed on these variants given the weak level of evidence.  
Functional Characterization 
To investigate whether the variants associated with lung cancer survival may modulate the mRNA 
expression in the lung tissues, we conducted eQTL analysis for the top 12 loci identified by overall and 
adenocarcinoma only analysis in a total of four independent studies, including three lung microarray 
studies and GTEx, based on a total of 1553 lung tissues. Variants that were shown to have significant cis-
effect on the mRNA expression of a nearby gene across all four studies are shown in Table 3 (Table 3).   
Three loci demonstrated consistent cis-effects across all 4 eQTL studies, including the only GWAS level 
significant variant, rs12875562 located at 13q22.2 with significant eQTL effect on LMO7 Downstream 
Neighbour (LMO7DN) gene expression with p-value of 9.40x10-7 in GTEx and 3.44x10-3 in Lung eQTL 
dataset and 9.40x10-7 in GTEx (Table 3 and Figure 1). Patients with the minor allele T had a poor survival 
and lower LMO7DN expressions. The strongest eQTL signal came from rs214346 located in CAPZB at 
1p36.13, which showed a consistent association with increased expression of CAPZB with in Lung eQTL 
dataset (p-value of 2.78x10-10) and in GTEx lung tissue (p=1.10x10-9) (Table 3 and Figure 2). Patients with 
minor A allele have better survival and lower CAPZB expression in lung tissue.  Finally, rs6569, located at 
9q34.3 in UBAC1 gene was found to be associated with decreased expression of UBAC1 in both Lung 
eQTL dataset (p= 1.14x10-3) and GTEx (p=9.20x10-14) (Table 3 and Figure 3). The minor allele A of this 
variant was associated with longer survival (HR=0.71, 95%CI=0.62-0.81, P=5.94×10−7) and a higher 




Based on the largest GWAS on lung cancer prognosis for never smokers conducted to date, we identified 
one locus that reached GWAS significance level at ch13q22 for patients with lung adenocarcinoma, and 
11 loci that provided suggestive evidence; among those ch4p14 was also associated lung cancer 
prognosis in Japanese population. Three of the top 12 loci were shown to affect mRNA expression in 
nearby genes as cis-eQTL across multiple studies, including the region with top signal in ch13q22, which 
provided additional level of evidence of the association related prognosis.    
The variant at the 13q22 locus is located adjacent to the LMO7 gene and LMO7 Downstream Neighbour 
(LMO7DN). LMO7 encodes a fibrous actin-binding protein that is commonly expressed in many human 
tissues, but particularly high in the lung epithelial cells.  It was suggested to be involved in the 
maintenance of epithelial architecture (35), and is considered to act as tumor suppresser gene, as LMO7 
knock-out mice were shown to develop spontaneous lung adenocarcinoma (36).  LMO7 expression was 
shown to be associated with lung cancer prognosis, but the direction of effect is not yet conclusive, 
which can be attributed to histological types included in the studies as well as other related genes in the 
same regulatory pathway (37,38).  We did not observe a consistent eQTL association with LMO7 per se, 
but with its downstream neighbour (LMO7DN) instead, with carriers of T allele exhibited poor prognosis 
for lung adenocarcinoma and lower LMO7DN expression.  This suggests that LMO7DN might play a more 
important role in lung tumor progression. This is the first time LMO7DN is identified as a gene associated 
with lung cancer prognosis at the genome-wide level.  
The region in ch1p36.13 encodes CAPZB gene, whose mRNA expression is affected by the variant with A 
allele associated with lower level of expression. CAPZB is a regulator of actin filament length that 
determines the mitotic cortex thickness during cell cycle progression, and it is associated with cell 
growth and motility in epithelioid sarcoma (39,40).  Variants within the same locus were previously 
12 
 
associated with total platelet mass (41), autoimmune related disorders such as Crohn’s disease and 
psoriasis (42,43). Other variants of the same gene have also been shown to be related to lung function 
(44,45), although the exact mechanism of how this gene is associated with lung cancer prognosis in 
never smokers is not clear.   
The region in ch9q34.3 encodes UBAC1, which is associated with innate immune system and Class I MHC 
mediated antigen processing. The sequence variants in this gene have been shown to be associated with 
interleukin-4 and interleukin-6 levels (46).  It has not been previously reported to be associated with 
cancer risk or prognosis. It is biologically plausible that this gene may modulate tumor progression 
through the innate immune pathway.   Finally, genetic variants of DLG2 located at 11q14.1 were 
previously shown to be associated with lung function (47) and familial squamous cell lung carcinoma 
(48), as well as anthropometric measurement such as body fat mass, fat and body mass index (49), 
which support a role of this gene in lung carcinogenesis and prognosis.  
Although previous studies have identified several genetic loci associated with lung cancer overall 
survival, primarily in smoking related lung cancer and early stage non-small cell lung cancer (14,17-19), 
we did not observe the association with those previously reported loci in our study of never smokers. 
This is not a surprise as we expect distinctive genetic architecture contribute to lung cancer survival in 
smokers and never smokers.  
For cross-ethnic generalizability, we observed only one association in ch4p14, encoding 
NWD2/KIAA1239 gene that was potentially generalizable between European and Japanese populations. 
This could be due to differences in the genetic background or different linkage disequilibrium patters 
underlying causal variants between European and Japanese population. In addition, the Japanese study 
has different characteristics such as distribution of sex, stage, treatment modality and overall survival, 
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which could also contribute to limited generalizability across different ethnicities.  Interestingly, the 
4p14 locus was previous reported to be associated with smoking behaviour(50).   
Our study has several limitations – First, potential heterogeneity between patient characteristics across 
studies may not be fully accounted for. In particular treatment information was not available for studies 
included in the OncoArray project and therefore could not be adjusted for in the model. However, it is 
expected that adjustment for clinical stage would mitigate the potential confounding effect of treatment 
as these two factors are highly correlated. Similarly, we do not have information on somatic mutations 
such as EGFR or ALK, which would affect prognosis. It is likely that the differences we observed across 
ethnic population are due to the differences in these mutations, which are markedly different by ethnic 
groups.  Second, our sample size might be underpowered due to relatively rare occurrence of lung 
cancer in never smokers, which can lead to potential false negative results. Nevertheless, this is the 
largest genome-wide analysis for lung cancer prognosis among never smokers conducted to date, and 
the results have high relevance considering the percentage of never smokers are increasing among lung 
cancer patients.   
In summary, we identified one locus at genome-wide significant level at 13q22 which was consistent 
with known role of genetic region encoding LMO7/LMO7DN in cancer pathology, along with several 
potential loci that would require further validations.  The integrated evidence from both the 
associations with lung cancer survival and eQTL are complementary and provide support of our 
hypothesis that inherited genetic factors affect lung cancer survival in never smokers.  Functional 
genomic experiments to assess the effect of altered gene regulation would be required to further 
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Table 1. Patient characteristics of the participating studies with European and Asian ancestry after quality control filters 
 
  European ancestry Asian 











HLCS  CAPUA   MDACC  LLP Japan 
Subtotal 208 327 349 92 59 88 240 42 71 93 1569 887 
MFT** 101 87 126 101.9 124 38.4 83 72.7 25.6 84.8 86.8 56.8 
MST* 20.1 27.7 54.3 49.6 13 87 53.5 10.09 42 14.7 34.6 23.9 
Vital status 
     
     
    
Dead 146 (70) 217 (66) 219 (63) 54 (59) 53 (90)  31 (35)   143 (60)   41 (98)   25 (35)   70 (75)  999 (65) 326 (37) 
Alive 62 (30) 110 (34) 130 (37) 38 (41) 6 (10) 57 (64)   97 (40)   1 (2)   46 (65)   23 (25)  570 (35) 561 (63) 
  
     
                   



















62.8 (12.5) 59.1 (9.1) 
Mean (SD) 
  
     




   
     
    
Male 69 (33) 104 (32) 117 (34) 61 (66) 11 (19)  20 (23)   82 (34)   6 (14)   31 (44)   57 (61)  558 (36) 133 (15) 
Female 139 (67) 223 (68) 232 (66) 31 (34) 48 (81)  68 (77)   158 (66)   36 (86)   40 (56)   36 (39)  1012 (64) 754 (85) 
  
          




   
                   
I-IIIA 74 (36) 183 (56) 244 (70) 55 (60) 10 (42)  50 (57)   112 (48)   10 (26)   19 (28)   43 (60)  804(53) 638 (72) 
IIIB-IV 134 (64) 144 (44) 105 (30) 37 (40) 14 (58)  37 (43)   122 (52)   28 (74)   49 (72)   29 (40)  695(46) 249 (28) 
  
          




   
                   
Adenocarcinoma 138 (69) 244 (75) 237 (68) 57 (62) 30 (51)  79 (90)   149 (62)   27 (64)   66 (93)   38 (41)  1065(68) 871 (98) 
Squamous  cell 14 (7) 26 (8) 16 (5) 7 (8) 10 (17)  5 (5)   9 (4)   5 (12)   1 (1)   36 (39)  129(8) 10 (1) 
Other 48 (24) 57 (17) 96 (27) 28 (30) 19 (32)  4 (6)   82 (34)   10 (24)   4 (6)   19 (20)  367(24) 6 (1) 
  
          




   
         
Yes 67 (32) 135 (41) 131 (38) 50 (54) n/a  n/a  n/a  n/a  n/a  n/a  383 (41) 639 (71) 
No 141 (68) 192 (59) 218 (62) 42 (46) n/a  n/a  n/a  n/a  n/a  n/a  551 (59) 248 (28) 
  
   
  
     




   
         
Yes 107 (51) 197 (60) 107 (31) 37 (40) 7 (12) n/a  n/a  n/a  n/a  n/a  455 (48) 222 (25) 
No 101 (49) 130 (40) 242 (69) 55 (60) 23 (39) n/a  n/a  n/a  n/a  n/a  496 (52) 665 (75) 
  
          




   
         
Yes 89 (43) 88 (27) 17 (5) 24 (26) 17 (29) n/a  n/a  n/a  n/a  n/a  235 (25) 26 (3) 
No 119 (57) 239 (73) 332 (95) 68 (74) 13 (22) n/a  n/a  n/a  n/a  n/a  703 (75) 861 (97) 




Table 2. The associations of sentinel variants representing each locus and overall survival of all lung cancer and adenocarcinoma   
 
     European ancestry  Japanese ancestry 
Location Lead SNP Gene¥ Effect Ref MAF HR* (95% CI) P I2 P(HET) MAF HR* (95% CI) P 
Lung cancer   
1p22.3 rs2911600 LINC01461 T C 0.033 2.02(1.53,2.66) 6.41E-07 36.2 0.180  0.066 0.88 (0.64,1.21) 0.438 
8q23.3 rs7822185 LINC00536 A G 0.035 2.71(1.83,4.00) 6.45E-07 49.7 0.113  0.063 1.05 (0.77,1.45) 0.729 
9q31.3 rs4978466 Intergenic  A G 0.292 0.76(0.69,0.85) 4.78E-07 38.6 0.164  0.083 0.99 (0.74,1.32) 0.976 
10p14 rs17143938 Intergenic T C 0.058 0.58(0.47,0.72) 5.99E-07 0 0.714  n/a n/a n/a 
Adenocarcinoma     
1p36.13 rs214346 CAPZB A G 0.424 0.72(0.63,0.82) 5.86E-07 29.5 0.225  0.366 1.01 (0.85,1.19) 0.900 
4p14 rs17603438 NWD2/KIAA1239 A G 0.100 0.50(0.38,0.66) 6.92E-07 0 0.588  0.452 0.79 (0.67,0.94) 0.007 
5q11.2 rs10041935 Intergenic A C 0.267 0.73(0.65,0.83) 6.84E-07 38.2 0.152  0.275 0.89 (0.75,1.06) 0.199 
7p21.3 rs10247578 Intergenic A G 0.403 1.38(1.23,1.55) 7.69E-08 32.7 0.191  0.203 0.88 (0.72,1.09) 0.258 
9q34.3 rs6569 UBAC1 A C 0.481 0.72(0.63,0.82) 5.94E-07 0 0.991  0.489 1.00 (0.87,1.16) 0.922 
10p15.3 rs17158233 Intergenic A G 0.024 3.68(2.23,6.09) 3.66E-07 0 0.628  0.090 1.22 (0.96,1.56) 0.100 
11q14.1 rs17148028 DLG2 T G 0.061 0.48(0.36,0.64) 5.66E-07 0 0.968  0.125 1.26 (0.97,1.65) 0.081 
13q22.2 rs12875562 Intergenic T C 0.122 1.71(1.41,2.07) 3.60E-08 0 0.959  0.112 1.11(0.87,1.42) 0.372 
* Hazard ratios (HRs) are from a meta-analysis of Cox-PH models adjusted by age, sex, clinical stage, principal components and when available by treatment. 
Ref: reference allele; Effect: the allele being evaluated; MAF : Minor allele frequency of the single nucleotide polymorphism; P : P-value; I2 : the I-squared 
statistic described the percentage of variation across studies that is due to heterogeneity; P(HET): the p-value for heterogeneity.  













a  based on variant location 
 b gene with the most significant eQTL association within a 1 Mb up and downstream of the transcription probe set.  
c eQTL P-value is based on meta-analysis of Laval University, University of British Columbia, University of Groningen studies.  
d Genotype-Tissue Expression (GTEx) database (http://www.gtexportal.org/home/) of RNAseq analysis in 515 lung human 
tissues (Release V7) 

















   Lung MicroArray eQTL GTEx eQTL for lung tissue d 
Location Lead SNP Genea Target Geneb P-valuec Target Geneb P-value 
1p36.13 rs214346 CAPZB CAPZB 2.78 x 10-10 CAPZB 1.10 x 10-9 
9q34.3 rs6569 UBAC1 UBAC1 1.14 x 10-3 UBAC1 9.20 x 10-14 
13q22.2 rs12875562 Intergenic LMO7DN 0.003 LMO7DN 9.40 x 10-7 
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Figure Legend  
 
Figure 1. The region ch13q22.2 (represented by rs12875562) and lung adenocarcinoma survival 
 
(a) Forest plots for study-specific hazard ratios (HR) and 95% confidence intervals (CI) 
(b) Kaplan-Meier plot by genotype of the sentinel variant over 5-year time period.  
(c) Regional plot that include the 1Mb around the sentinel variant rs12875562. X-axis represent the 
chromosome position and Y-axis represent –log10 (p-value) with color representing the linkage 
disequilibrium with the sentinel variant in r² 
(d) eQTL p-value from the GTEx data based on normal lung tissues  
(e) eQTL P-values from the Lung eQTL dataset: Laval University, University of British Columbia (UBC) and 
University of Groningen.  The left y axis represents gene expression levels in the lung adjusted for age, 




Figure 2. The region ch1p36.13 (represented by rs214346) and lung adenocarcinoma survival 
 
(a) Forest plots for study-specific hazard ratios (HR) and 95% confidence intervals (CI) 
(b) Kaplan-Meier plot by genotype of the sentinel variant over 5-year time period.  
(c) Regional plot that include the 1Mb around the sentinel variant rs214346. X-axis represent the 
chromosome position and Y-axis represent –log10 (p-value) with color representing the linkage 
disequilibrium with the sentinel variant in r² 
(d) eQTL p-value from the GTEx data based on normal lung tissues 
(e) eQTL P-values from the Lung eQTL dataset: Laval University, University of British Columbia (UBC) and 
University of Groningen.  The left y axis represents gene expression levels in the lung adjusted for age, 
sex and smoking status. The x axis represents genotyping groups for rs214346 
 
Figure 3. The region ch9q34.3 (represented by rs6569) and lung adenocarcinoma survival 
 
(a) Forest plots for study-specific hazard ratios (HR) and 95% confidence intervals (CI) 
(b) Kaplan-Meier plot by genotype of the sentinel variant over 5-year time period.  
(c) Regional plot that include the 1Mb around the sentinel variant rs6569. X-axis represent the 
chromosome position and Y-axis represent –log10 (p-value) with color representing the linkage 
disequilibrium with the sentinel variant in r² 
(d) eQTL p-value from the GTEx data based on normal lung tissues  
(e) eQTL P-values from the Lung eQTL dataset: Laval University, University of British Columbia (UBC) and 
University of Groningen.  The left y axis represents gene expression levels in the lung adjusted for age, 
sex and smoking status. The x axis represents genotyping groups for rs6569 
 
 



